FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides
- PMID: 28346110
- DOI: 10.1089/nat.2017.0665
FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides
Keywords: antisense oligonucleotide; eteplirsen; nusinersen; spinal muscular atrophy; therapy.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
